Polyetheretherketone Double Functionalization with Bioactive Peptides Improves Human Osteoblast Response.

Autor: Cassari, Leonardo¹ (AUTHOR) leonardo.cassari@phd.unipd.it, Balducci, Cristian¹ (AUTHOR) cristian.balducci@phd.unipd.it, Messina, Grazia M. L.² (AUTHOR) gml.messina@unict.it, Iucci, Giovanna³ (AUTHOR) giovanna.iucci@uniroma3.it, Battocchio, Chiara³ (AUTHOR) chiara.battocchio@uniroma3.it, Bertelà, Federica³ (AUTHOR) federica.bertela@uniroma3.it, Lucchetta, Giovanni¹ (AUTHOR) giovanni.lucchetta@unipd.it, Coward, Trevor⁴ (AUTHOR) trevor.coward@kcl.ac.uk, Di Silvio, Lucy⁴ (AUTHOR) lucy.di_silvio@kcl.ac.uk, Marletta, Giovanni² (AUTHOR) gmarletta@unict.it, Zamuner, Annj^1,5 (AUTHOR) annj.zamuner@unipd.it, Brun, Paola⁶ (AUTHOR) paola.brun.1@unipd.it, Dettin, Monica¹ (AUTHOR) monica.dettin@unipd.it

Publikováno v: Biomimetics (2313-7673). Dec2024, Vol. 9 Issue 12, p767. 16p.

αvβ3 integrin-targeted magnetic resonance imaging in a pancreatic cancer mouse model using RGD-modified liposomes encapsulated with Fe-deferoxamine.

Autor: Yoshimoto, Mitsuyoshi¹ (AUTHOR) miyoshim@ncc.go.jp, Hayakawa, Takuya¹ (AUTHOR), Yamaguchi, Masayuki¹ (AUTHOR), Kimura, Sadaaki¹ (AUTHOR), Fujii, Hirofumi¹ (AUTHOR)

Publikováno v: PLoS ONE. 9/24/2024, Vol. 19 Issue 9, p1-13. 13p.

TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias.

Autor: Breinholt VM; Ascendis Pharma A/S, Hellerup, Denmark (V.M.B., C.E.R., P.H.M., M.K.-H.); and Ascendis Pharma GmbH, Heidelberg, Germany (F.F., A.B., J.Z., U.H.) vmb@ascendispharma.com., Rasmussen CE; Ascendis Pharma A/S, Hellerup, Denmark (V.M.B., C.E.R., P.H.M., M.K.-H.); and Ascendis Pharma GmbH, Heidelberg, Germany (F.F., A.B., J.Z., U.H.)., Mygind PH; Ascendis Pharma A/S, Hellerup, Denmark (V.M.B., C.E.R., P.H.M., M.K.-H.); and Ascendis Pharma GmbH, Heidelberg, Germany (F.F., A.B., J.Z., U.H.)., Kjelgaard-Hansen M; Ascendis Pharma A/S, Hellerup, Denmark (V.M.B., C.E.R., P.H.M., M.K.-H.); and Ascendis Pharma GmbH, Heidelberg, Germany (F.F., A.B., J.Z., U.H.)., Faltinger F; Ascendis Pharma A/S, Hellerup, Denmark (V.M.B., C.E.R., P.H.M., M.K.-H.); and Ascendis Pharma GmbH, Heidelberg, Germany (F.F., A.B., J.Z., U.H.)., Bernhard A; Ascendis Pharma A/S, Hellerup, Denmark (V.M.B., C.E.R., P.H.M., M.K.-H.); and Ascendis Pharma GmbH, Heidelberg, Germany (F.F., A.B., J.Z., U.H.)., Zettler J; Ascendis Pharma A/S, Hellerup, Denmark (V.M.B., C.E.R., P.H.M., M.K.-H.); and Ascendis Pharma GmbH, Heidelberg, Germany (F.F., A.B., J.Z., U.H.)., Hersel U; Ascendis Pharma A/S, Hellerup, Denmark (V.M.B., C.E.R., P.H.M., M.K.-H.); and Ascendis Pharma GmbH, Heidelberg, Germany (F.F., A.B., J.Z., U.H.).

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2019 Sep; Vol. 370 (3), pp. 459-471. Date of Electronic Publication: 2019 Jun 24.

Screening of MMP-13 Inhibitors Using a GelMA-Alginate Interpenetrating Network Hydrogel-Based Model Mimicking Cytokine-Induced Key Features of Osteoarthritis In Vitro.

Autor: Hu, Qichan¹ (AUTHOR), Williams, Steven L.² (AUTHOR), Palladino, Alessandra¹ (AUTHOR), Ecker, Melanie¹ (AUTHOR) melanie.ecker@unt.edu

Publikováno v: Polymers (20734360). Jun2024, Vol. 16 Issue 11, p1572. 21p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.